A search result from Polskie Radio on the approval status of tirzepatide for weight loss, with no further detail provided beyond the question itself.
Recap by typeshit. Full story at www.polskieradio.pl.
12:50
Alex Wallace, who bills himself as a peptide expert, gives his response to what Dr. Mike has said about peptides. Details beyond the title are thin.
A Facebook post credits Novo Nordisk's GLP-1 drugs with strong results in obesity and type 2 diabetes, plus lower risk of other conditions.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
Polskie Radio covers the approval of Novo Nordisk's Wegovy in China. The link carries no further detail on timing or terms.
The two drugs brought in $14.9 billion of Lilly's $23.0 billion fiscal Q2 revenue while US prices fell 9%, Trefis says. The Q3 report is expected around October 29.
Novo Nordisk is lowering what Wegovy costs in China, a fresh move in the race for the country's obesity drug market. No figures were given.
Loading…